Observational study of lipid profile and LDL particle size in patients with metabolic syndrome.

Background: The atherogenic lipoprotein phenotype is characterized by an increase in plasma triglycerides, a decrease in high-density lipoprotein cholesterol (HDLc), and the prevalence of small, dense-low density lipoprotein cholesterol (LDLc) particles. The aim of this study was to establish the importance of LDL particle size measurement by gender in a group of patients with Metabolic Syndrome (MS) attending at a Cardiovascular Risk Unit in Primary Care and their classification into phenotypes.

Subjects And Methods: One hundred eighty-five patients (93 men and 92 women) from several areas in the South of Spain, for a period of one year in a health centre were studied.

[LDL concentration and particle size after treatment with rosiglitazone in patients with diabetes mellitus type 2].

Background And Objective: The effects of rosiglitazone on the lipid profile are controversial, with related increases in the concentration of total and LDL cholesterol. Our objective is to evaluate the evolution of the concentration and size of LDL particles in a group of patients with type 2 diabetes mellitus taking rosiglitazone.

Patients And Methods: We studied 30 patients under treatment with oral antidiabetics to whom rosiglitazone was added to their initial therapy.